Search: WFRF:(Houssiau Frederic)
> (2015-2019) >
Off-label use of ri...
Off-label use of rituximab for systemic lupus erythematosus in Europe
-
- Ryden-Aulin, Monica (author)
- Karolinska Institutet
-
- Boumpas, Dimitrios (author)
- National and Kapodistrian University of Athens
-
- Bultink, Irene (author)
- Amsterdam Rheumatology and Immunology Center
-
show more...
-
- Rubio, Jose Luis Callejas (author)
- Hospital Clínico Universitario San Cecilio
-
- Caminal-Montero, Luis (author)
- Asturias General Hospital
-
- Castro, Antoni (author)
- Rovira i Virgili University (URV)
-
- Ruiz, Agustín Colodro (author)
- Pasaje Nueva Victoria
-
- Doria, Andrea (author)
- University of Padova
-
- Dorner, Thomas (author)
- Charité - University Medicine Berlin
-
- Gonzalez-Echavarri, Cristina (author)
- University of the Basque Country
-
- Gremese, Elisa (author)
- Catholic University of the Sacred Heart, Rome
-
- Houssiau, Frederic A. (author)
- Saint-Luc University Hospital
-
- Huizinga, Tom (author)
- Leiden University Medical Centre
-
- Inanc, Murat (author)
- Istanbul University
-
- Isenberg, David (author)
- Royal Free Hospital
-
- Iuliano, Annamaria (author)
- Azienda Ospedaliera San Camillo Forlanini
-
- Jacobsen, Soren (author)
- University of Copenhagen
-
- Jimenez-Alonso, Juan (author)
- Hospital Clínico Universitario San Cecilio
-
- Kovacs, Laszlo (author)
- University of Szeged
-
- Mariette, Xavier (author)
- Center For Immunology Of Viral Infections And Autoimmune Diseases
-
- Mosca, Marta (author)
- University of Pisa
-
- Nived, Ola (author)
- Lund University,Lunds universitet,Reumatologi och molekylär skelettbiologi,Sektion III,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Rheumatology,Section III,Department of Clinical Sciences, Lund,Faculty of Medicine,Skåne University Hospital
-
- Oristrell, Joaquim (author)
- Autonomous University of Barcelona
-
- Ramos-Casals, Manuel (author)
- Institutd' Investigacions Biomèdiques August Pi iSunyer (IDIBAPS)
-
Rascon, Javier (author)
-
- Ruiz-Irastorza, Guillermo (author)
- University of the Basque Country
-
- Sáez-Comet, Luis (author)
- Miguel Servet University Hospital
-
- Cervello, Gonzalo Salvador (author)
- University and Polytechnic Hospital la Fe
-
- Sebastiani, Gian Domenico (author)
- Azienda Ospedaliera San Camillo Forlanini
-
- Squatrito, Danilo (author)
- University of Florence
-
- Szucs, Gabriella (author)
- University of Debrecen
-
- Voskuyl, Alexandre (author)
- Amsterdam UMC - Vrije Universiteit Amsterdam
-
- Van Vollenhoven, Ronald (author)
- Karolinska Institutet
-
show less...
-
(creator_code:org_t)
- 2016-09-06
- 2016
- English.
-
In: Lupus Science and Medicine. - : BMJ. - 2053-8790. ; 3:1
- Related links:
-
http://dx.doi.org/10... (free)
-
show more...
-
https://lupus.bmj.co...
-
https://lup.lub.lu.s...
-
https://doi.org/10.1...
-
http://kipublication...
-
show less...
Abstract
Subject headings
Close
- Objectives: Rituximab (RTX) is a biological treatment used off-label in patients with systemic lupus erythematosus (SLE). This survey aimed to investigate the off-label use of RTX in Europe and compare the characteristics of patients receiving RTX with those receiving conventional therapy. Methods: Data on patients with SLE receiving RTX were taken from the International Registry for Biologics in SLE retrospective registry and complemented with data on patients with SLE treated with conventional therapy. For nationwide estimates of RTX use in patients with SLE, investigators were asked to provide data through case report forms (CRFs). Countries for which no data were submitted through CRFs, published literature and/or personal communication were used, and for European countries where no data were available, estimates were made on the assumption of similarities with neighbouring countries. Results: The estimated off-label use of RTX in Europe was 0.5%-1.5% of all patients with SLE. In comparison with patients with SLE on conventional therapy, patients treated with RTX had longer disease duration, higher disease activity and were more often treated with immunosuppressives. The most frequent organ manifestations for which either RTX or conventional therapy was initiated were lupus nephritis followed by musculoskeletal and haematological. The reason for treatment was, besides disease control, corticosteroid-sparing for patients treated with conventional therapy. Conclusions: RTX use for SLE in Europe is restrictive and appears to be used as a last resort in patients for whom other reasonable options have been exhausted.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Reumatologi och inflammation (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Rheumatology and Autoimmunity (hsv//eng)
Publication and Content Type
- for (subject category)
- ref (subject category)
Find in a library
To the university's database
- By the author/editor
-
Ryden-Aulin, Mon ...
-
Boumpas, Dimitri ...
-
Bultink, Irene
-
Rubio, Jose Luis ...
-
Caminal-Montero, ...
-
Castro, Antoni
-
show more...
-
Ruiz, Agustín Co ...
-
Doria, Andrea
-
Dorner, Thomas
-
Gonzalez-Echavar ...
-
Gremese, Elisa
-
Houssiau, Freder ...
-
Huizinga, Tom
-
Inanc, Murat
-
Isenberg, David
-
Iuliano, Annamar ...
-
Jacobsen, Soren
-
Jimenez-Alonso, ...
-
Kovacs, Laszlo
-
Mariette, Xavier
-
Mosca, Marta
-
Nived, Ola
-
Oristrell, Joaqu ...
-
Ramos-Casals, Ma ...
-
Rascon, Javier
-
Ruiz-Irastorza, ...
-
Sáez-Comet, Luis
-
Cervello, Gonzal ...
-
Sebastiani, Gian ...
-
Squatrito, Danil ...
-
Szucs, Gabriella
-
Voskuyl, Alexand ...
-
Van Vollenhoven, ...
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Rheumatology and ...
- Articles in the publication
-
Lupus Science an ...
- By the university
-
Lund University
-
Karolinska Institutet